Abstract
Within the framework of a two-component model of the COVID-19 epidemic, taking into account the special role of superspreaders, we consider the impact of the recovery factor and quarantine measures on the course of the epidemic, as well as the possibility of a second wave of morbidity. It is assumed that there is no long-term immunity in asymptomatic superspreaders who have undergone the infection, and the emergence of long-term immunity in those who have undergone severe illness. It is shown that, under these assumptions, the relaxation of quarantine measures leads to the resumption of virus circulation among asymptomatic superspreaders. Depending on the characteristics of the quarantine, its removal may or may not lead to a renewed wave of daily morbidity. A criterion for the occurrence of repeated wave of morbidity is proposed based on the analysis of the final phase of the first wave. Based on this criterion, the repeated wave of the epidemic is predicted in New Zealand. A natural explanation is given for the decrease in lethality among the infected against the background of an absolute increase in their number.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding used
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approval required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
One figure added
Data Availability
Only open data sourses used